These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 32999240)

  • 1. Rapidly Progressing Aseptic Abscesses in a Patient with Ulcerative Colitis.
    Yamaguchi Y; Nakagawa M; Nakagawa S; Nagao K; Inoue S; Sugiyama T; Izawa S; Hijikata Y; Ebi M; Funaki Y; Ogasawara N; Sasaki M; Kasugai K
    Intern Med; 2021 Mar; 60(5):725-730. PubMed ID: 32999240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple ulcerative colitis-associated aseptic abscesses successfully treated with infliximab: a case report.
    Toba T; Ikegami R; Nogami A; Watanabe N; Fujii K; Ogawa Y; Hojo A; Fujimoto A; Matsuda T
    Clin J Gastroenterol; 2023 Aug; 16(4):537-542. PubMed ID: 37097421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Ulcerative colitis complicated by pyoderma gangrenosum and multiple aseptic abscesses].
    Kita A; Hashimoto Y; Sato K; Itoi Y; Kasuga K; Tanaka H; Hosaka H; Kuribayashi S; Uraoka T
    Nihon Shokakibyo Gakkai Zasshi; 2022; 119(11):1014-1021. PubMed ID: 36351620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dosing interval and diagnosis predict infliximab levels in patients with inflammatory bowel disease on maintenance treatment.
    Krajcovicova A; Batovsky M; Gregus M; Hlista M; Durina J; Leskova Z; Sturdik I; Gojdic M; Jalali Y; Koller T; Toth J; Huorka M; Hlavaty T
    Acta Gastroenterol Belg; 2018; 81(4):465-470. PubMed ID: 30645913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infliximab for pediatric patients with ulcerative colitis: a phase 3, open-label, uncontrolled, multicenter trial in Japan.
    Tajiri H; Arai K; Kagimoto S; Kunisaki R; Hida N; Sato N; Yamada H; Nagano M; Susuta Y; Ozaki K; Kondo K; Hibi T
    BMC Pediatr; 2019 Oct; 19(1):351. PubMed ID: 31607268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and safety of infliximab biosimilar CT-P13 in treating ulcerative colitis: a real‑life experience in IBD primary centers.
    Tursi A; Allegretta L; Chiri S; Della Valle N; Elisei W; Forti G; Lorenzetti R; Mocci G; Penna A; Pranzo G; Ricciardelli C; Picchio M
    Minerva Gastroenterol Dietol; 2017 Dec; 63(4):313-318. PubMed ID: 28293938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A case of a simple ulcer associated with ulcerative colitis that demonstrated a good clinical response to infliximab].
    Kishi M; Sou S; Ishihara H; Terabe H; Yasaka M; Kuhara K; Takeda T; Shimokoube M; Morimitsu Y; Miyazono K
    Nihon Shokakibyo Gakkai Zasshi; 2015; 112(9):1682-8. PubMed ID: 26346358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre.
    Kolar M; Duricova D; Bortlik M; Hruba V; Machkova N; Mitrova K; Malickova K; Lukas M; Lukas M
    Dig Dis; 2017; 35(1-2):91-100. PubMed ID: 28147356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcomes of infliximab treatment and predictors of response in 195 patients with ulcerative colitis: a hospital-based cohort study from Korea.
    Seo H; Chang K; Lee SH; Song EM; Kim GU; Seo M; Lee HS; Hwang SW; Yang DH; Kim KJ; Ye BD; Byeon JS; Myung SJ; Yang SK; Park SH
    Scand J Gastroenterol; 2017 Aug; 52(8):857-863. PubMed ID: 28502189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tracheobronchitis in ulcerative colitis: a case report of therapeutic response with infliximab and review of the literature.
    Horgan L; Mulrennan S; D'Orsogna L; McLean-Tooke A
    BMC Gastroenterol; 2019 Nov; 19(1):171. PubMed ID: 31675916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infliximab for very early-onset inflammatory bowel disease: A tertiary center experience in Japan.
    Takeuchi I; Kaburaki Y; Arai K; Shimizu H; Hirano Y; Nagata S; Shimizu T
    J Gastroenterol Hepatol; 2020 Apr; 35(4):593-600. PubMed ID: 31425641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association Between Infliximab Drug and Antibody Levels and Therapy Outcome in Pediatric Inflammatory Bowel Diseases.
    Ungar B; Glidai Y; Yavzori M; Picard O; Fudim E; Lahad A; Haberman Y; Shouval DS; Weintraub I; Eliakim R; Ben-Horin S; Weiss B
    J Pediatr Gastroenterol Nutr; 2018 Oct; 67(4):507-512. PubMed ID: 29901557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histological healing after infliximab induction therapy in children with ulcerative colitis.
    Wiernicka A; Szymanska S; Cielecka-Kuszyk J; Dadalski M; Kierkus J
    World J Gastroenterol; 2015 Oct; 21(37):10654-61. PubMed ID: 26457025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Steroid refractory severe ulcerative colitis after kidney transplantation successfully treated with infliximab.
    Kojima K; Takada J; Kamei M; Kubota M; Ibuka T; Shimizu M
    Clin J Gastroenterol; 2023 Dec; 16(6):848-853. PubMed ID: 37715899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Analysis of clinical characteristics and drug treatment of inflammatory bowel disease in children: a single center study].
    Zhang R; Zhong XM; Gong YZ; Ma X; Zhu D; Ning HJ; Wang FP; Zou JZ; Zhang YL
    Zhonghua Er Ke Za Zhi; 2020 Jul; 58(7):570-575. PubMed ID: 32605341
    [No Abstract]   [Full Text] [Related]  

  • 17. A comparison of short-term therapeutic efficacy between infliximab and tacrolimus for moderate to severe ulcerative colitis.
    Yamagami H; Nishida Y; Nagami Y; Hosomi S; Yukawa T; Otani K; Tanaka F; Taira K; Kamata N; Tanigawa T; Shiba M; Watanabe T; Fujiwara Y
    Rom J Intern Med; 2017 Sep; 55(3):151-157. PubMed ID: 28222041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Increased Serum N-Terminal Telopeptide of Type I Collagen, a Biochemical Marker of Increased Bone Resorption, Is Associated with Infliximab Therapy in Patients with Crohn's Disease.
    Sugimoto K; Ikeya K; Iida T; Kawasaki S; Arai O; Umehara K; Watanabe F; Tani S; Oishi S; Osawa S; Yamamoto T; Hanai H
    Dig Dis Sci; 2016 Jan; 61(1):99-106. PubMed ID: 26254083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel Disease.
    van Hoeve K; Dreesen E; Hoffman I; Van Assche G; Ferrante M; Gils A; Vermeire S
    Ther Drug Monit; 2019 Jun; 41(3):317-324. PubMed ID: 30633088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Evaluation of efficacy and comparative frequency of adverse events in patients with ulcerative colitis receiving the original infliximab and its biosimilar. One year of observation].
    Knyazev OV; Shkurko TV; Kagramanova AV; Lishchinskaya AA; Zvyaglova MY; Korneeva IA; Babayan AF; Parfenov AI
    Ter Arkh; 2019 Aug; 91(8):41-46. PubMed ID: 32598753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.